How long does it take to stop taking Capmatinib?

Capmatinib (Capmatinib) is a targeted drug for the treatment of METexon14 skip mutation non-small cell lung cancer (NSCLC). Its medication time depends on the patient's condition. There is currently no clear standard medication cycle. Generally, patients need to continue taking capmatinib until disease progression or intolerable adverse effects occur. If the patient is stable and tolerates the drug well, the drug can be taken long-term to maintain efficacy.

When a patient's disease progresses, that is, the tumor becomes resistant to capmatinib and the drug's efficacy decreases, it may be necessary to stop capmatinib and switch to other treatment options. Resistance usually occurs 6 to 12 months after the start of treatment, but the specific time varies depending on individual differences. Before drug resistance occurs, doctors may evaluate the patient's condition through imaging and genetic testing to ensure that discontinuation of medication is scientific and safe.

During capmatinib treatment, some patients may experience serious adverse reactions, such as interstitial lung disease (ILD), severe impairment of liver function, or other life-threatening side effects. In this case, your doctor may consider suspending the medication or stopping it entirely. If the adverse reactions are mild, the drug can usually be continued after dose adjustment or symptomatic treatment, so the decision to discontinue the drug needs to be evaluated by a professional doctor.

A small number of patients may achieve complete response (CR) during treatment, which means no visible tumor lesions on imaging tests. Whether such patients need to continue taking medication must be determined based on the doctor's advice. Even if complete remission is achieved, there may still be a risk of relapse after discontinuation of medication, so patients need to be followed regularly after discontinuation of medication to monitor their condition. In most cases, doctors will recommend that patients continue maintenance treatment to reduce the risk of recurrence.

For patients who discontinue capmatinib, whether due to treatment failure or complete remission, subsequent management is critical. Doctors may develop new treatment options, such as switching to other targeted drugs, immunotherapy, or chemotherapy. Regular follow-up after discontinuation of medication, including imaging examinations and genetic testing, can help detect changes in the condition in time and take appropriate measures. Patients should work closely with their doctors to ensure that their condition is controlled within an acceptable range after discontinuation of medication.

xa0

Reference materials

Novartis. Capmatinib (Tabrecta) Prescribing Information.